A Truncated IL-17RC Peptide Ameliorates Synovitis and Bone Destruction of Arthritic Mice

详细信息    查看全文

• 作者：Yuxuan Du ; Yulong Tong ; Wentong Mei ; Junhui Jia ; Menglin Niu ; Wei Cao ; Weiwei Lou ; Shentao Li ; Zhanguo Li ; W. Alexander Stinson ; Huihui Yuan and Wenming Zhao
• 刊名：Advanced Healthcare Materials
• 出版年：2016
• 出版时间：November 23, 2016
• 年：2016
• 卷：5
• 期：22
• 页码：2911-2921
• 全文大小：3142K
• ISSN：2192-2659

文摘

Peptide-based therapy, such as modified peptides, has attracted increased attention. IL-17 is a promising therapeutic target for autoimmune diseases, and levels of circulating bioactive IL-17 are associated with rheumatoid arthritis severity. In this study, a modified truncated IL-17RC is generated to ameliorate inflammation and bone destruction in arthritis. The truncated IL-17RC binds to both IL-17A and IL-17F with higher binding capacity compared to nonmodified IL-17RC. In addition, the truncated IL-17RC reduces the secretion of inflammatory and osteoclastogenic factors induced by IL-17A/F in vitro. Moreover, the administration of truncated IL-17RC dramatically improves symptoms of inflammation and inhibited bone destruction in collagen-induced arthritis mice. Collectively, these data demonstrate that modified truncated IL-17RC peptide may be a more effective treatment strategy in the simultaneous inhibition of both IL-17A and IL-17F signaling, whereas the existing agents neutralize IL-17A or IL-17F alone. These suggest that the truncated IL-17RC may be a potential candidate in the treatment of inflammatory associated bone diseases.